Effect of

Mai E Abdelhady, Khaled H Elmosalamy, Asmaa A A Kattaia, Mai A Samak

Abstract readComparative Study

In one paragraph

Article in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mai E AbdelhadyDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.

Khaled H ElmosalamyDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.

Asmaa A A KattaiaDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.

Mai A SamakDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0002-5837-3921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesDyslipidemia is a prevalent metabolic disorder closely linked to cardiovascular complications and muscular pathologies, often managed using statins such as simvastatin. However, statin-induced myopathy remains a significant treatment-limiting side effect, necessitating the exploration of safe, natural alternatives.

methodsForty animals were allocated to the control and high-fat diet (HFD) groups. After 4 weeks, the dyslipidemic rats were subdivided into untreated, simvastatin-treated, and

results

conclusionThese molecular and ultrastructural benefits position

Indexed as

DyslipidemiasMuscle, SkeletalSimvastatinSpirulinaAnimalsCreatine KinaseDiet, High-FatMaleMalondialdehydeMuscular DiseasesRatsCreatine KinaseMalondialdehydeSimvastatinBcl2dyslipidemianutraceuticalsoxidative stressSpirulina platensisstatin-induced myopathyTGF-β1

Identifiers

PMID40843759

DOI10.3390/medsci13030137

PMCPMC12372102

What OpenQuestion holds

Texttitle and abstract

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.